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Abstract
The cannabinoid receptor 1 (CB1), a member of the class A G-protein-coupled receptor (GPCR) 
family, possesses an observable level of constitutive activity. Its activation mechanism, however, 
has yet to be elucidated. Previously we discovered dramatic changes in CB1 activity due to single 
mutations; T3.46A, which made the receptor inactive, and T3.46I and L3.43A, which made it 
essentially fully constitutively active. Our subsequent prediction of the structures of these mutant 
receptors indicated that these changes in activity are explained in terms of the pattern of salt-
bridges in the receptor region involving transmembrane domains 2, 3, 5, and 6. Here we identified 
key salt-bridges, R2.37 + D6.30 and D2.63 + K3.28, critical for CB1 inactive and active states, 
respectively, and generated new mutant receptors that we predicted would change CB1 activity by 
either precluding or promoting these interactions. We find that breaking the R2.37 + D6.30 salt-
bridge resulted in substantial increase in G-protein coupling activity and reduced thermal stability 
relative to the wild-type reflecting the changes in constitutive activity from inactive to active. In 
contrast, breaking the D2.63 + K3.28 salt-bridge produced the opposite profile suggesting this 
interaction is critical for the receptor activation. Thus, we demonstrate an excellent correlation 
with the predicted pattern of key salt-bridges and experimental levels of activity and 
conformational flexibility. These results are also consistent with the extended ternary complex 
model with respect to shifts in agonist and inverse agonist affinity and provide a powerful 
framework for understanding the molecular basis for the multiple stages of CB1 activation and that 
of other GPCRs in general.
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INTRODUCTION
G protein-coupled receptors (GPCRs) play a central role in biological processes by 
transmitting signals from various external stimuli, including neurotransmitters, hormones, 
and light, across the cell membrane. The cannabinoid receptor one (CB1) is a member of the 
rhodopsin-like GPCR family that binds Δ9-THC, the psychoactive component of marijuana, 
and exerts its pharmacological effects via intracellular signaling cascades. CB1 is one of the 
most abundant GPCRs in the mammalian brain and is found in the basal ganglia, 
cerebellum, and hippocampus. Like other GPCRs, activation by agonists, induces CB1 to 
undergo conformational changes that promote activation of the coupled guanine nucleotide-
binding protein (G-protein) which then stimulates downstream effector proteins, such as 
inhibition of adenylate cyclase activity and calcium channels and activation of inwardly 
rectifying potassium channels.1
Early thinking about GPCR function assumed the existence of just two GPCR states, the 
“off” (R) and “on” (R*) modes representing the inactive and active states of the receptor, 
respectively.2 This binary complex model suggests that an agonist shifts the equilibrium in 
favor of the active form of the receptor that can couple to G-protein. This model was later 
extended to account for the activity of constitutively active mutant (CAM) receptors that can 
couple to G-protein in a ligand-independent manner.3,4 Since CAMs are pre-coupled to G 
protein, they are characterized by enhanced affinity for agonists, decreased affinity for 
inverse agonists, and increased basal functional activity. Interestingly, CAMs are known for 
many GPCRs, including rhodopsin,5 β1 adrenergic receptor,6 histamine H1 receptor,7 
angiotensin receptor type 1,8 opioid receptor,9 and the CB1 cannabinoid receptor.10,11 More 
recently it has become clear that GPCRs can adopt multiple distinct conformations 
displaying different states of receptor activation resulting in different signaling efficacies.12 
Thus, the transition from inactive to active forms of a GPCR may include several distinct 
conformational substates that can be differentially stabilized by G proteins or by different 
ligands – opening the way for highly selective therapeutic agents—or by mutations that 
stabilize a particular receptor conformation.13–15 Many GPCRs16,17 including the CB1 
receptor18 possess constitutive activity in the absence of ligand. Therefore, wild-type CB1 is 
at a pivot point and can become more fully activated by agonists such as CP55940 and Δ9-
THC or inhibited by the inverse agonists SR141716A and AM251.19 Using the wild-type 
and mutant forms of the CB1 receptor, this study presents for the first time a detailed 
activation mechanism that provides a structural basis for the constitutive activity exhibited 
by GPCRs, how they become fully inactive, and what structural changes allow them to 
become more active.
We previously showed that the single amino acid substitution of leucine at position 3.43 with 
alanine, or of threonine 3.46 with isoleucine, caused the slightly active CB1 receptor to 
become highly constitutively active.10,11 Note the positions of the transmembrane (TM) 
helix residues are indicated using the Ballesteros-Weinstein amino acid numbering system20 
throughout the text. In this numbering system, the most conserved residue in each TM helix 
is given the location of 0.50. This number is preceded by the TM number. All other residues 
in the TM helix are numbered relative to this residue. Thus, the L3.43 and T3.46 residues are 
approximately two and one turn above, respectively, the arginine residue of the highly 
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conserved DRY motif in TM3, which has been shown to form ionic interactions with the 
glutamic acid residues at position 3.49 and 6.30 in the crystal structure of inactive 
rhodopsin.21 In contrast, we showed that an alanine substitution of T3.46 resulted in a fully 
inactive receptor. Consistent with the characteristics of a CAM, the more active T3.46I and 
L3.43A receptors show enhanced and decreased affinities for agonists and inverse agonists, 
respectively, relative to the wild-type receptor while the inactive T3.46A receptor exhibits 
the reverse profile.
To interpret the dramatic changes in function observed for the wild-type, L3.43A, T3.46A, 
and T3.46I receptors, we used the GEnSeMBLE (GPCR Ensemble of Structures in 
Membrane Bilayer Environment) method22 to predict the three-dimensional structures of 
their TM domains and found that their stability and activity correlates with the predicted 
pattern of key salt-bridges.23 Our previous study shows that the differences between the 
active and inactive predicted structures agree well with those observed between active and 
inactive crystallographically characterized GPCRs,21,24–38 giving credence to the predicted 
structures. While many diverse types of contacts and interhelical interactions stabilize each 
activation state, our work focuses on the salt-bridges, especially the intracellular ones. 
Changes in hydrophobic interactions, aromatic stacking, and hydrogen bonds in the TM 
bundle are important, but they do not provide the strongest indication for activation.
Our computational predictions of CB1 suggest that transition between distinct patterns of 
salt-bridges is critical for receptor activity. Based on these predicted structures and the 
hypothesis that the salt-bridges control the propensity for activation, we predicted a series of 
new CB1 mutants expected to either preclude or promote these ionic interactions which we 
expected to exhibit specific levels of constitutive activity relative to the wild-type receptor. 
Indeed, our computational structural prediction data showed the pattern of key salt-bridges is 
conserved among the mutant receptors that are expected to have a similar level of 
constitutive activity suggesting those may be critical for receptor activation. In particular, the 
R2.37 + D6.30 and D2.63 + K3.28 salt-bridges are identified in inactive and active CB1 
receptors, respectively. We then experimentally constructed these mutants to break these 
salt-bridges and found that they exhibit substantial shifts in G protein coupling, thermal 
stability, and ligand binding affinity relative to the wild-type, consistent with our expected 
changes in constitutive activity and conformational flexibility. This excellent correlation of 
experimental activation propensity with the role of key salt-bridges in our predicted 
structures provides new insight into the interconnection between structure and function of 
CB1. These results support and extend the concepts of the extended ternary complex model 
with respect to shifts in agonist and inverse agonist affinity.6,39,40 This provides a new 
powerful framework for understanding the molecular basis for the stages of CB1 activation 
in particular and by inference that of other GPCRs.
MATERIALS AND METHODS
Receptor structure prediction
The structures of CB1 wild-type and mutant receptors were predicted as described 
previously.23 The ensemble of low energy conformations of each receptor was predicted 
using the first-principles based GEnSeMBLE method.22 All simulations used the Dreiding 
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force field.41 The ensemble of the best 10 conformations (by lowest energy) for each mutant 
was analyzed in detail for the presence of salt-bridge, hydrogen-bond, and hydrophobic 
interactions. Briefly, the seven individual TMs were predicted based on the octanol 
hydrophobicity scale42 using the PredicTM22 method and extended using helical structure 
predictions from three secondary structure prediction servers: Porter Protein Secondary 
Structure Prediction Server,43,44 APSSP2: Advanced Protein Secondary Structure Prediction 
Server,45,46 and PSIPRED: Protein Prediction Server.47–49 The separate helices were built 
and optimized with OptHelix22 before the TMs aligned to multiple crystal templates. We 
compared the energies resulting from the turkey beta 1 adrenergic receptor, bovine 
rhodopsin receptor, human β2 adrenergic receptor, and human adenosine A2A receptor 
templates because they were the only crystallographically characterized GPCRs available at 
the time of these computational studies. The turkey β1 adrenergic receptor crystal provided 
the lowest energy helix packing conformations for the wild-type CB1 receptor, which is a 
reasonable result because out of the four receptors, the turkey β1 adrenergic receptor had the 
highest percentage identity of conserved TM residues with respect to the CB1 wild-type 
receptor at 28.45%. We completed the following procedure with this template.
To predict the structures of single and double mutant receptors, the target residues were 
mutated in the OptHelix optimized TM2 or TM3 from the wild-type receptor using 
SCREAM (Side Chain Rotamer Excitation Analysis Method).50 Each helix rotation angle 
(η) was sampled using the BiHelix method,51 where the side chain rotamers were optimized 
using SCREAM. For the lowest energy conformation from the BiHelix protocol, we 
performed a local sampling of helix tilt angle (θ), sweep angle (φ), and rotation angle (η) for 
all pairs of interacting helices while optimizing the side chain rotamers using SCREAM. 
From this, the top 2000 conformations were selected and reordered using more accurate 
conformational energies obtained by explicitly constructing the 7-helix bundles. Each of 
them was minimized for 10 steps in a vacuum. Finally, the 10 lowest energy structures were 
selected according to the average energy rank. Four different types of energies were 
calculated for each minimized receptor including the charged total energy, the neutralized 
total energy, the charged interhelical energy, and the neutralized interhelical energy. The 
total energy refers to the energy of the entire receptor, whereas the interhelical energy is 
defined as the energy between interacting helices. In the charged state, the acidic residues 
(glutamic acid and aspartic acid) have a negative charge, and the basic residues (lysine, 
protonated histidine, and arginine) have a positive one. Under the neutralized conditions, the 
acidic residues gain a hydrogen atom and the basic residues lose one. Each receptor is 
ranked according to these four energy types, and these respective ranks are averaged to give 
a final rank representing the average energy rank. We examined a small selection of 10 final 
receptor conformations. These 10 receptors are found to all share similar characteristics, 
which define the “consensus structure.” The receptor conformations shown in Figure 1(A) 
are those that faithfully represent the consensus structure.
CB1 expression and membrane preparation
The plasmid DNA encoding human CB1 receptors was prepared as previously described.52 
HEK293 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% 
fetal bovine serum and 3.5 mg/mL glucose at 37°C in 5% CO2. For transient expression of 
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the receptors, HEK293 cells were seeded at 1 million cells/100 mm dish on the day prior to 
transfection using the calcium phosphate precipitation method.53 Twenty-four hours post-
transfection, membranes of transfected cells expressing the wild-type or mutant receptors 
were prepared using nitrogen cavitation as previously described.10
GTPγS binding assay
Approximately 5 μg of membrane preparations from HEK293 cells expressing CB1 
receptors were incubated for 60 min at 30°C in a total volume of 500 μL GTPγS binding 
assay buffer (50 mM Tris-HCl, pH 7.4, 3 mM MgCl2, 0.2 mM EGTA, and 100 mM NaCl) 
with 0.1 nM [35S]GTPγS (1250 Ci/mmol, PerkinElmer Life Sciences, Boston, MA), 1 μM 
GDP, and 0.1% (w/v) BSA. The levels of basal and CP55940-induced GTPγS binding were 
measured in the absence of ligand and presence of 1 μM unlabeled CP55940, respectively. 
Non-specific binding was determined with 10 μM unlabeled GTPγS (Sigma, St Louis, MO). 
The reaction was terminated by rapid filtration to separate the membrane-bound fraction 
from the free through Whatman GF/C filters (Brandel Inc., Gaithersburg, MD). The 
radioactivity of the membrane-bound [35S]GTPγS trapped in the filters was determined by 
liquid scintillation counting. Pilot experiments were conducted to ensure that there is no 
depletion of ligand, nucleotides, and G proteins in the assay system.
Measurement of receptor thermal stability
A previously established method for determining receptor stability as a function of 
temperature in the absence of ligand was employed.54,55 Approximately 5 μg of membrane 
preparations from the CB1 receptor-expressing HEK293 cells were incubated at the 
specified temperature for 30 min in the absence of ligand. Control samples for each receptor 
were kept on ice for 30 min. For every mutant, the different membrane aliquots were each 
heated at a single temperature ranging from 30°C to 100°C. After incubation, the samples 
were quenched on ice, re-homogenized, and added to TME buffer containing a near-
saturating concentration of [3H]CP55940 (147.9 Ci/mmol, PerkinElmer Life Sciences, 
Boston, MA) for further incubation for 60 min at 30°C. The radiolabeled-ligand was used at 
a concentration 10-fold above Kd for each receptor as determined by saturation binding,56 to 
minimize the impact of any possible affinity change due to heat treatment. Nonspecific 
binding was determined in the presence of 1 μM unlabeled ligand. Reactions were 
terminated by filtration with a Brandel cell harvester through Whatman GF/C filter paper. 
Radioactivity was measured by liquid scintillation counting. Three independent thermal 
stability measurements were carried out each in duplicate. The data were analyzed by non-
linear regression using GraphPad Prism Software (GraphPad Software Inc., San Diego, CA) 
to obtain the slope and midpoint (apparent Tm) at 50% loss of specific binding as described 
previously.54,55
Radioligand binding assay
Saturation binding assays were performed as previously described.56 Briefly, approximately 
5 μg of membranes were incubated at 30°C for 60 min with [3H]CP55940 (147.9 Ci/mmol, 
PerkinElmer Life Sciences, Boston, MA) or [3H]SR141716A (43 Ci/mmol, PerkinElmer 
Life Sciences, Boston, MA) in a total volume of 200 μL or 500 μL TME buffer (25 mM 
Tris-HCl, 5mM MgCl2, and 1 mM EDTA, pH 7.4) containing 0.1% fatty acid-free bovine 
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serum albumin. At least nine radiolabeled-ligand concentrations were used to determine Kd 
values of the receptors. Nonspecific binding was determined in the presence of 1 μM of 
unlabeled ligand. Reactions were terminated by filtration with a Brandel cell harvester 
through Whatman GF/C filter paper followed by four washes with ice-cold TME buffer to 
remove unbound radioactivity. Radioactivity was measured by liquid scintillation counting.
Data analysis
All data points represent the mean ± SE of at least three independent experiments performed 
in duplicate. For saturation radioligand binding assay, the Kd and Bmax values were 
calculated by nonlinear regression using GraphPad Prism Software (GraphPad Software 
Inc., San Diego, CA). The values for the wild-type and mutant receptors were compared 
using analysis of variance (ANOVA) followed by Bonferroni's post hoc test for significance. 
P values of <0.05 were considered to be statistically significant.
RESULTS
Predicting interactions key to CB1 receptor activation
We previously demonstrated experimentally that the amino acids at position T3.46 and 
L3.43 are key to receptor activation.10,11 Mutating T3.46 to isoleucine or L3.43 to alanine 
yielded highly constitutively active receptors, while replacing T3.46 with alanine inactivated 
the constitutively active wild-type CB1 receptor. To identify a structural basis for these 
experimental results, we predicted the ensemble of energetically favorable conformations for 
the wild-type, L3.43A, T3.46I, and T3.46A receptors using the first-principles-based 
GEnSeMBLE method.22 Figure 1(A) shows the predicted structures of these receptors in 
terms of the key salt-bridges. We also found some differences in aromatic residue 
interactions and in hydrogen bonding interactions, however, we consider these changes to be 
less important in explaining the dramatic change from inactive to active structures.
The wild-type CB1 receptor is unique from other GPCRs because it has a threonine residue 
(T3.46) one turn above the conserved R3.50. In other GPCRs, this residue is either an 
alanine or a leucine. Our computational predictions indicate that CB1 contains a unique 
hydrogen bond involving T3.46 and S2.45. The S2.45 residue usually participates in the 
highly conserved 2-3-4 hydrogen bond network as observed in other crystallized GPCRs. By 
mutating T3.46 to alanine or leucine, we break this hydrogen bond connecting TM2 and 3, 
as seen in Figure 1(A.2). In the T3.46I mutant, the larger hydrophobic isoleucine side-chain 
pushes the surrounding helices, including TM6, away in order to provide enough room to 
avoid side-chain clashes. In the T3.46A mutant, the alanine residue is smaller than threonine 
and can fit in-between TMs 2 and 6. These two helices do not have to be as far away to 
avoid clashes as they would in the wild-type or T3.46I receptors. The T3.46A residue, 
however, does not interact with S2.45, so TM2 is rotated to optimize other polar interactions. 
In the L3.43A mutant, the threonine residue is left intact and thus so is the S2.45 and T3.46 
hydrogen bond. The position of TM6 in relation to TM3 can change because the new alanine 
residue takes up less space than the original leucine one. The residues in the middle of TM6, 
such as V6.43, would clash with the 3.43 residue if the WT sequence had the L3.43A mutant 
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conformation. In the L3.43A mutant, the extracellular end tilts towards TM3, but the 
intracellular end moves away breaking the R3.50 + D6.30 interaction.
A comparison of the Cα-RMSD measure for the TM region across three of the functionally 
distinct structures, WT, T3.46A, and T3.46I, shows it to be 2.54 Å for the WT-T3.46A pair, 
2.12 Å for the WT-T3.46I pair, and 2.86 Å for the T3.46A-T3.46I pair. A comparison of 
these numbers for the GPCRs crystallized in at least two distinct conformations was done. 
This Cα-RMSD measure for the common TM region for human β2 adrenergic receptor in 
the inactive (PDB ID: 2RH1) and the active (PDB ID: 3SN6) forms is: 2.48 Å. This measure 
for rhodopsin (PDB ID: 1U19) and metarhodopsin II (PDB ID: 3PQR) is 2.34 Å. For the 
adenosine A2A receptor, the partially active form (PDB ID: 3QAK) deviates from the 
inactive form (PDB ID: 3EML) by 1.61 Å. The observed structural changes in the CB1 
receptor in different functional forms are comparable in magnitude with that observed in the 
crystallized GPCRs. The smaller inactive-to-active deviation in the A2A receptor is a 
manifestation of the fact that the active receptor is only partially active and cannot yet 
accommodate a G protein.
Comparing the predicted conformations for T3.46A, wild-type, T3.46I, and L3.43A, we 
found excellent correlation of the salt-bridge patterns with the experimentally determined 
extent of receptor activation (e.g. inactive, partially and fully active receptors) as 
summarized in Figure 1(B). We found that (1) only the fully inactive receptor has an R2.37 
+ D6.30 salt-bridge; note, the salt-bridge and hydrogen bond interactions are indicated by a 
plus (+) and a dash (–), respectively, throughout the text. (2) The weakly active wild-type 
receptor has R3.50 + D6.30 and D3.49 + K4.41 salt-bridges in addition to a D2.63 + K3.28 
salt-bridge. (3) The highly constitutively active T3.46I and L3.43A receptors have neither of 
the R3.50 + D6.30 and D3.49 + K4.41 salt-bridges but both retain the D2.63 + K3.28 salt-
bridge. Our interpretation of these results is that the presence of the R2.37 + D6.30 salt-
bridge leads to a complete loss of activity even if the R3.50 + D6.30 and D3.49 + K4.41 salt-
bridges are also present (as they are in T3.46A). At the other end of the spectrum, the D2.63 
+ K3.28 salt-bridge is required for full receptor activity (as in L3.43A and T3.46I) and it 
may be accompanied by a R5.71 + D6.30 salt-bridge (found in T3.46I) but this is not 
necessary for activation. However, when the D2.63 + K3.28 salt-bridge is accompanied by 
the R3.50 + D6.30 and D3.49 + K4.41 salt-bridges, they constrain the receptor to a less 
active state, and thus although the wild-type receptor also has this salt-bridge, it is only 
weakly active. These interpretations are consistent with the occurrence of this R3.50 + 
D6.30 salt-bridge between the DRY motif in TM3 and the D/E residue on the cytoplasmic 
side of TM6 in many GPCRs believed to be important for stabilizing the receptor inactive 
conformation.57,58
To evaluate the significance of these non-covalent interactions in receptor activation, we 
proceeded to predict a series of receptors with single and double point mutations which by 
the above concepts were expected to have specific changes in their activity and then 
experimentally tested their biochemical properties. The predicted structures highlighting the 
amino acids mutated, the R2.37 and D2.63 residues in TM2 and the L3.43 and T3.46 in 
TM3, are shown in Figure 2(A). Figure 2(B) illustrates the computationally predicted pattern 
of salt-bridges (R2.37 + D6.30, R3.50 + D6.30, D3.49 + K4.41, R5.71 + D6.30, and D2.63 + 
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K3.28) for the wild-type and some of CB1 mutant receptors. In addition to the highly active 
T3.46I and L3.43A and fully inactive T3.46A receptors analyzed previously,10,11 we 
combined mutations that individually lead to constitutively active or inactive receptors 
(L3.43A, T3.46I, or T3.46A) with amino acid substitutions (R2.37A, R2.37Q, D2.63A) that 
break potential ionic interactions, R2.37 + D6.30 or D2.63 + K3.28. These include the 
R2.37Q/T3.46A, R2.37A/T3.46A, and D2.63A/L3.43A receptors. Given the pattern of salt-
bridges identified in the consensus structures, these receptors are grouped by their expected 
levels of constitutive activity (e.g. highly active, partially active, or inactive). Figure 2(C) 
shows a full list of the CB1 receptors generated in this study in terms of predicted extent of 
constitutive activity. These include the L3.43A/T3.46I, L3.43A/T3.46A, and R2.37A/
D2.63A/L3.43A receptors in addition to the receptors shown in Figure 2(B). We expect the 
L3.43A/T3.46I receptor to display a level of constitutive activity comparable to or higher 
than that of the L3.43A or the T3.46I receptor alone, since the individual mutations both 
lead to high constitutive activity. In contrast, the L3.43A/T3.46A mutant receptor is expected 
to possess somewhat reduced constitutive activity relative to the L3.43A mutation alone 
since it is combined with the inactivating alanine substitution at position T3.46.10 Since our 
structure prediction indicates the salt-bridge between R2.37 and D6.30 is critical for 
maintaining the T3.46A receptor inactive, we expect that two mutant receptors, R2.37A/
T3.46A and R2.37Q/T3.46A, will break the salt-bridge between R2.37 and D6.30. The 
D2.63A/L3.43A receptor was also constructed and cannot form the activating D2.63 + 
K3.28 salt-bridge. Interestingly, computational analysis indicates that this mutant receptor 
adopts the inactivating R2.37 + D6.30 salt-bridge. Thus, we expect breaking the resulting 
R2.37 + D6.30 salt-bridge in the D2.63A/L3.43A receptor would result in regaining of some 
constitutive activity. This is further tested by characterizing the triple mutant, R2.37A/
D2.63A/L3.43A. Collectively, we hypothesized that the R2.37 + D6.30 and D2.63 + K3.28 
salt-bridges may be critical for inactive and constitutively active conformations, respectively; 
however, if the latter is accompanied by a D3.49 + K4.41 and/or a R3.50 + D6.30 salt-
bridge, like the wild-type, full receptor activity cannot be obtained. Some residues identified 
in Figure 1(B) (D3.49 and D6.30) have been excluded from this mutational study because 
they appear to be involved in multiple interactions making it difficult to interpret the data. 
Moreover, our predictions and others57,59,60 suggested that they (as well as K3.28 and 
K4.41) may have a secondary role in receptor assembly and/or ligand interactions in 
addition to activation. The R5.71 + D6.30 salt-bridge has also been omitted in this study 
because this is present in the T3.46I receptor, but not in the L3.43A receptor, suggesting this 
interaction is not essential for receptor activation. The resulting mutant receptors were then 
evaluated for their biochemical properties to ascertain the extent to which receptor activity 
could be correlated with the non-covalent interactions identified.
Basal [35S]GTPγS binding reveals the level of constitutive activity of the CB1 receptors
To measure directly the functional activity of the receptors, we investigated [35S]GTPγS 
binding to HEK293 membranes expressing the CB1 wild-type and mutant receptors. The 
CB1 receptor is known to couple to pertussis toxin sensitive inhibitory G (Gi/o) protein. 
Thus, the [35S]GTPγS binding assay is suitable for evaluating the G protein association with 
this receptor,61 For basal G protein coupling activity, we measured [35S]GTPγS binding to 
the membranes expressing the CB1 receptors in the absence of ligand. The level of GTPγS 
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binding for the T3.46A and D2.63A/L3.43A receptors is 53.2 fmol/mg and 53.3 fmol/mg, 
respectively, which is comparable to the level of a mock-transfected sample (53.2 fmol/mg) 
[Fig. 3(A)]. Thus, the residual activity observed by us (~ 53 fmol/mg) and others62,63 is non-
CB1 mediated and those receptors are in the fully inactive state. Two double mutants, the 
R2.37Q/T3.46A and R2.37A/T3.46A receptors, regained some constitutive activity, 
evidenced by the level of GTPγS binding of 77.0 fmol/mg and 72.5 fmol/mg, respectively. 
Interestingly, the triple mutant R2.37A/D2.63A/L3.43A also exhibited some level of 
constitutive activity (68.1 fmol/mg). Although these two double mutants and triple mutant 
displayed less constitutive activity than the wild-type (98.5 fmol/mg), the level is 
nonetheless remarkable; the data suggest that the salt-bridge involving the arginine at 
position 2.37 may be critical for the inactive conformation and when this interaction breaks, 
some constitutive activity is regained. The levels of GTPγS binding are only marginally 
different between the L3.43A/T3.46A and wild-type receptors. The L3.43A and T3.46I, and 
L3.43A/T3.46I receptors displayed the greatest constitutive activity with a similar level of 
GTPγS binding (112.3 fmol/mg, 114.5 fmol/mg, and 121.5 fmol/mg, respectively). Taken 
together, the experimentally measured levels of basal activity for the CB1 mutant receptors 
agree exceedingly well with the computationally predicted patterns of ionic interactions 
[Figs. 2(C) and 3(A)].
CP55940-stimulated [35S]GTPγS binding suggests the maximal level of possible G protein 
coupling
To further evaluate how agonists impact the activity of the receptors, we investigated the 
agonist-promoted [35S]GTPγS binding to membranes expressing the CB1 receptors. Figure 
3(B) shows the level of CP55940-induced [35S]GTPγS binding. Interestingly, regardless of 
the wide range of constitutive activity (basal level) exhibited by each receptor, CP55940 
induced a similar level of GTPγS binding, suggesting this ligand may induce a comparable 
conformation for all the receptors examined with two exceptions (the D2.63A/L3.43A and 
T3.46A receptors). It is important to note that 1 μM CP55940 treatment induced little to no 
increase of GTPγS binding relative to the basal level for the L3.43A, T3.46I, and L3.43A/
T3.46I receptors, suggesting these receptors may already adopt an active conformation 
comparable to a fully active receptor even in the absence of agonists. Intriguingly, although 
two inactive mutant receptors, D2.63A/L3.43A and T3.46A displayed a significant increase 
in GTPγS binding with 1 μM CP55940, the levels were significantly lower than that of the 
wild-type [Fig. 3(B)]. This suggests that these inactive mutants are not able to be fully 
activated either because of a lack of particular non-covalent interactions critical for full 
receptor activation or because of the existence of a remaining constraint such as the TM2 + 
TM6 or TM3 + TM6 coupling that stabilizes the inactive state even upon CP55940 binding. 
Although the R2.37A/D2.63A/L3.43A receptor regained some constitutive activity in the 
absence of ligand, it was not fully activated by CP55940 suggesting the important role of the 
D2.63 residue in full receptor activation. Note that CP55940 treatment showed no change in 
the mock-transfected sample indicating that the CP55940-induced [35S]GTPγS is CB1 
receptor-mediated.
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Thermal stabilities of the CB1 receptors are consistent with a spectrum of active states
It is generally accepted that the active conformation in its apo form is less stable relative to 
the inactive conformation.64 Indeed, CAMs of many GPCRs have been shown to adopt the 
conformation having increased flexibility with marked instability.64,65 To obtain an 
experimental measurement of the relative stability of the CB1 receptors, we preformed 
thermal denaturation assays in the absence of ligand as previously established by many 
groups.54,55 The term “stability” used in this study is defined as the ability of the receptor to 
maintain a correctly folded state, especially within its binding pocket believed to form 
within the helical bundle. Since the wild-type receptor has been shown to possess significant 
constitutive activity,18,66 it can become either inactive or fully active, and consequently its 
temperature midpoint of the denaturation curve, Tm, should vary accordingly with the 
mutations described. As shown in Figure 4(A) and Table I, the thermal denaturation for the 
L3.43A/T3.46I receptor leads to the lowest Tm of 55.8 ± 1.2° for the series followed by the 
L3.43A and T3.46I receptors with 57.2 ± 1.6°C and 58.1 ± 0.5°C, respectively. The 
difference in Tm values between the L3.43A and T3.46I receptors is not statistically 
significant. The L3.43A/T3.46A receptor also exhibits substantially less stability (Tm = 60.7 
± 1.1°C) relative to the wild-type receptor, which denatures with a Tm = 64.5 ± 1.1°C. 
Consistent with the trend observed from basal GTPγS binding data, two receptors with 
double substitutions, R2.37Q/T3.46A and R2.37A/T3.46A, and the triple mutant receptor 
R2.37A/D2.63A/L3.43A showed enhanced thermal stability relative to the wild-type 
receptor with Tm values of 67.2 ± 1.0°C, 68.1 ± 0.9°C, and 69.8 ± 1.2°C, respectively [Fig. 
4(B) and Table I]. Our data also indicates that the inactive receptors, T3.46A and D2.63A/
L3.43A, adopted the most stable conformation among the receptors we tested, indicated by 
their Tm (71.4 ± 1.8°C and 72.1 ± 2.1°C, respectively). Taken together with the basal G 
protein coupling data, we demonstrate that in the absence of ligand, the single and double 
mutations on TM2 and TM3 progressively impact the receptor's thermal stability correlating 
well with predicted conformational changes, and in turn changes in the equilibrium between 
the inactive (R) and highly active receptor (R*). Figure 4(C) shows an excellent correlation 
between the Tm and the receptor activity level determined from GTPγS binding with an R2 
value of 0.9722. This indicates that the conformational change adopted by these mutants 
results in a corresponding functional change, as the receptor becomes thermodynamically 
less stable with increasing activity.
Ligand binding affinity reflects extent of basal activity
One of the remarkable characteristics of CAMs is that their ligand binding affinity shifts due 
to pre-coupling to the G protein. In general, CAMs are characterized by enhanced affinity 
for agonists and decreased affinity for inverse agonists, whereas inactive GPCRs exhibit the 
opposite characteristics; decreased affinity for agonists and enhanced affinity for inverse 
agonist.6,39,40 To evaluate the predicted correlations between the key intramolecular 
interactions of the receptor with ligand binding profiles and consequently test the predictions 
of the extended ternary complex model on the series of mutant receptors shown in Figure 
2(B), we carried out saturation binding experiments using the CB1 agonist [3H]CP55940 
and the inverse agonist [3H]SR141716A. In agreement with ligand binding properties for 
other GPCR CAMs,6,39,40 saturation binding analysis indicates the T3.46I and L3.43A 
receptors display an improved affinity for CP55940 by sixfold with Kd values of 0.31 ± 0.04 
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nM and 0.32 ± 0.13 nM, respectively, relative to the wild-type receptor (Kd of 1.78 ± 0.32 
nM) (Table II). The inactive mutant receptor T3.46A displays a sixfold reduced affinity for 
CP55940 compared to the wild-type receptor with a Kd value of 9.83 ± 1.12 nM. This is 
consistent with our previous homologous competition binding data for these receptors.10,11
As predicted, the L3.43A/T3.46I receptor exhibits a Kd value (0.28 ± 0.02 nM) comparable 
to the individual single mutant receptors, L3.43A and T3.46I, whereas the L3.43A/T3.46A 
showed a wild-type-like affinity for CP55940 with Kd of 1.10 ± 0.23 nM.
Since the salt-bridge between R2.37 and D6.30 cannot form in the R2.37A/T3.46A, R2.37Q/
T3.46A, and R2.37A/D2.63A/L3.43A receptors, these receptors exhibited ligand binding 
affinity profiles between those of the T3.46A and wild-type receptors with Kd values of 5.58 
± 0.32 nM, 6.21 ± 1.11 nM, and 7.63 ± 0.89, respectively, confirming that the R2.37 is 
critical for the CB1 inactive conformation.
In order to evaluate the importance of D2.63 on the transition to an active conformation, we 
considered the D2.63A/L3.43A mutant, which was predicted to be inactive. Indeed, this 
mutant receptor showed a markedly decreased affinity for CP55940 with a Kd of 12.74 
± 2.13 nM, which is comparable to the inactive T3.46A receptor, confirming the theoretical 
prediction that D2.63 is required for activation of this receptor. No significant differences 
were observed between the Bmax values of any of the mutant receptors tested.
In accordance with the extended ternary complex model,3 agonists shift the equilibrium 
toward a state where active receptors (R*) predominate, whereas inverse agonists increase 
the inactive receptor (R) population. Therefore, this model predicts that constitutively active 
receptors possess increased affinity for agonist, as we demonstrated with CP55940. The 
affinity changes of CB1 receptors with single and double mutations for the agonist CP55940 
inspired us to also assess the effect of the mutations on the affinity for inverse agonist using 
[3H]SR141716A. The saturation binding parameters for [3H]SR141716A for the CB1 
mutant receptors along with the wild-type receptor are shown in Table II. Interestingly, the 
overall rank order of affinity for [3H]SR141716A was opposite to that for [3H]CP55940. For 
example, the D2.63A/L3.43A (0.64 ± 0.07 nM) and T3.46A (0.61 ± 0.09 nM) receptors 
exhibited threefold greater affinity than the wild-type (2.11 ± 0.42 nM) for [3H]SR141716A. 
The R2.37Q/T3.46A (1.59 ± 0.22 nM), R2.37A/T3.46A (1.67 ± 0.26 nM), and R2.37A/
D2.63A/L3.43A (1.48 ± 0.20) receptors showed slightly lower but not statistically 
significant Kd values for inverse agonist binding relative to the wild-type receptor. The 
L3.43A/T3.46A receptor exhibited a fourfold lower affinity with a Kd value of 7.50 ± 0.46 
nM. Two single mutants, L3.43A and T3.46I, and a double mutant L3.43A/T3.46I displayed 
a sevenfold and sixfold lower affinity, respectively, than the wild-type receptor. All mutant 
receptors showed negligible Bmax changes in [3H]SR141716A binding, showing similar 
expression levels among the receptors tested in this study. Taken together, shifts in affinity 
for [3H]CP55940 and [3H]SR141716A suggest that the mutant receptors exist in different 
and graded states of receptor activation in the absence of ligand, consistent with the 
extended ternary complex model.3 This is especially apparent if the Kd ratios for each 
mutant and wild-type receptors are compared (Table II). Thus, the GTPγS data, thermal 
stability, and ligand binding properties demonstrate that the single and double mutations on 
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TM2 and TM3 impact the receptor's functional activity, providing an array of constitutive 
activity from the inactive (R) to highly active receptor states (R*).
DISCUSSION
A central question driving GPCR structural studies involves how the individual TMs move 
and interact during activation and how this rearrangement affects their interactions with 
downstream signaling molecules, such as G-proteins, β-arrestins, and G-protein coupled 
receptor kinases. To address this fundamental question, we predicted the CB1 receptor 
structures for the wild-type and several mutants and found systematic differences of specific 
inter-helical interactions critical to different levels of receptor activation. We observed shifts 
in G-protein coupling activity, receptor stability, and ligand binding affinity consistent with 
our computational predictions. Consequently, we have generated a collection of CB1 
receptors involving minimal modifications that collectively exhibit a continuum of 
constitutive activity. These include two mutant receptors, D2.63A/L3.43A and T3.46A, that 
we predicted would be inactive and which subsequent experiments, indeed, showed to 
display inactive receptor properties. These involved mutations that lead to functions opposite 
of those exhibited by CAMs. The properties of the D2.63A/L3.43A receptor are particularly 
remarkable because computational analysis indicates that it adopts the inactivating R2.37 + 
D6.30 salt-bridge while experiments show the profiles corresponding to an inactive receptor 
(Table II); this mutant receptor cannot form the D2.63 + K3.28 activating salt-bridge and 
thus is inactive despite the inclusion of the L3.43A mutation. It is important to note that we 
included only one residue of each of the two salt bridges (e.g. D2.63 and R2.37) for 
mutational study, since each respective partners (D6.30 and K3.28, respectively) is likely 
involved in multiple interactions critical for receptor activation and ligand binding.59,60,67,68 
Therefore, our mutational study does not firmly rule out the possibility that the salt-bridges 
did not involve the D6.30 and K3.28 residues. However, the computationally predicted 
formation of the R2.37 + D6.30 salt-bridge in the D2.63A/L3.43A receptor was tested by the 
triple mutant, D2.63A/L3.43A/R2.37A (Figs. 3 and 4, Tables I and II), and the data further 
support that the R2.37 residue is critical for receptor activity likely through interaction with 
D6.30. We predict that a similar salt-bridge pattern can be achieved for more than a single 
CAM. For example, we demonstrated that both T3.46I and L3.43A are highly constitutively 
active and share key salt-bridge interactions, such as the D2.63 + K3.28 [Fig. 1(B)]. 
Similarly, two inactive mutants T3.46A and D2.63A/L3.43A retained the TM2 + TM6 lock. 
Thus, our proposed activation mechanism reveals key global interactions responsible for 
receptor activation rather than specific local interaction changes. Given that GPCRs can 
adopt multiple activation states, our activation mechanism provides a structural template that 
can be expanded further to test for other CAMs. Since the first CAM was generated for the 
α1B-adrenergic receptor leading to spontaneous G-protein activation in the absence of an 
agonist,6,69 single amino acid substitutions in various regions of different GPCRs have been 
shown to produce enhanced constitutive activity.70,71 These regions include the cytoplasmic 
extensions of TMs 2, 3, 6, and 7, indicating that these are sensitive to receptor activity. 
Intriguingly, recent studies demonstrate that mutations on the extracellular loops 2 and 3 can 
also result in enhanced constitutive activity in the C5a and adenosine A2b receptors.72,73 
Molecular modeling data suggest that some mutations on the extracellular loops alter the 
Ahn et al. Page 12
Proteins. Author manuscript; available in PMC 2016 May 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
interactions between the loops and TMs, which in turn impact the TM helix packing 
arrangement involving TMs 2, 3, and 7.72 In addition to the crystal structures of inactive 
GPCRs, a few GPCRs have been recently crystallized in the active conformation including 
rhodopsin, the β2-adrenergic receptor and the A2A adenosine receptor.25,74–77 These active 
state structures reveal some common patterns of conformational changes providing 
snapshots of the “active” forms. For example, metarhodopsin II, Gs-bound β2-adrenergic 
receptors, and the A2A adenosine receptor displayed significant conformational changes due 
to alteration of the inter-helical hydrogen bond network involving residues in TMs 3, 5, 6 
and 7 near the ligand binding pocket.75,77,78 This suggests that although the residues 
interacting with agonists are largely receptor specific, they seem to undergo a similar 
conformational change via these TMs upon activation. A similar pattern of TM movement 
upon activation was observed in our predicted CB1 structures.23 In addition, the “active” 
forms exhibit a rearrangement (tilting and rotation) of TM6 and neutralization of D3.49 in 
the DRY motif of TM3. Those adjustments allow for accommodation of the G-protein at the 
cytoplasmic side of the receptors.25,74,76,77 Our predicted receptor conformations are 
consistent with this, indicating that CB1 also undergoes a similar activation mechanism 
involving TM6 and TM3. However, our data also indicate the existence of a TM2 + TM6 
salt-bridge in the inactive conformation, which is unique to the CB1 receptor and points to 
an additional element in its mechanism of activation. Breaking the R2.37 + D6.30 and 
forming the D2.63 + K3.28 salt-bridge are critical for constitutive activity.
In addition to disruption of key salt-bridges,79,80 our paradigm for GPCR activation involves 
rigid body movement of the TMs due to changes in the hydrogen bonding network81,82 and 
aromatic residue interactions.83,84 For example, our predicted structures contain multiple 
hydrogen bonds involving TM2 and TM4 that have also been found in the crystallized 
GPCRs.21,25,85-87 We predict a H2.41-K4.41 hydrogen bond in the wild-type receptor and a 
Y2.40-R4.39 hydrogen bond in both wild-type and T3.46I mutant receptors. A Y2.41-K4.43 
hydrogen bond has been observed experimentally in the inactive human A2A adenosine 
receptor structure,85 and a Y2.41-E4.39 hydrogen bond has been observed in multiple 
crystal structures including bovine rhodopsin,21 the active opsin,86,87 and the active meta 
II.25 However, since the presence of these non-covalent interactions varies among different 
receptor states, our computational predictions strongly suggest that intracellular ionic 
interactions are the driving force leading to the dramatic changes in activity among the 
receptors we tested. This is consistent with MD simulations on the β2 adrenergic receptor.88
It is well accepted that high constitutive activity requires the absence of intramolecular 
interactions that constrain the receptor in the R state.89 Our proposed helix packing pattern 
shows that the highly constitutively active mutant receptors, L3.43A/T3.46I, L3.43A, and 
T3.46I lack the intracellular ionic coupling across TMs, such as the most conserved TM3 + 
TM6 ionic lock and the TM2 + TM6 salt-bridge are present in the inactive form of CB1. 
Instead, the active receptors seem to possess salt-bridge interactions between neighboring 
TMs (e.g. TM2 + TM3 and TM5 + TM6) resulting in a larger diameter (11.64 Å) at the 
cytoplasmic end of TM3 and TM6 than that of the T3.46A (8.47 Å) or wild-type (8.93 Å) 
receptors. This conformational change may facilitate accommodation of the C-terminal α-
helix of the Gα protein during receptor activation.87 The lack of the constraining salt-bridges 
that are present in the inactive mutants and slightly active wild-type receptor allows the 
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CAM receptors to relax into the R* conformation and the transition to this conformation 
results in enhanced conformational flexibility and lower stability. To measure the structural 
stability of GPCRs, a thermal stability measurement was developed for GPCRs by many 
groups.55,64 Initially, GPCR thermal stability was measured to screen for more stable 
conformations for structural analysis such as X-ray crystallography.90,91 We applied these 
measurements to each receptor to evaluate the correlation between receptor activity and 
conformational instability in the absence of ligand during the denaturing step (heat 
treatment) at various temperatures and subsequently determined the stability by quantitative 
measurement of the loss of ligand binding ability as described previously.54,55 Our data 
demonstrate that the more active conformations are less stable and denature at lower 
temperatures (the apparent Tm). In addition, the good correlation between receptor stability 
and activity, and the pattern of agonist and inverse agonist affinity for each receptor suggests 
that the stability change observed is not merely due to the point mutation per se. Rather it is 
due to global conformational changes involving multiple TMs (TMs 2, 3, 5, and 6) 
stemming from differential salt-bridge patterns. This is consistent with the predicted 
structures for those receptors with mutations in TMs 2 and 3. The observation that the 
inactive single mutant T3.46A is much more stable than the wild-type receptor strongly 
indicates that structural changes resulting from this single mutation are sufficiently 
substantial to provide enhanced stability of the mutant receptor; this is consistent with the 
changes observed in the predicted structures.
Intriguingly, although two inactive mutant receptors, D2.63A/L3.43A and T3.46A displayed 
a significant increase in GTPγS binding with 1 μM CP55940 treatment, the levels were 
substantially lower than that of the wild-type [Fig. 3(B)]. This may suggest that these 
inactive mutants can only partially mimic the activated conformations upon agonist binding. 
Perhaps ligand-induced full activation is not possible due to their lack of interactions critical 
for full receptor activation or else the existence of remaining constraints that stabilize the 
inactive state even upon CP55940 binding. Moreover, treatment with even higher 
concentrations of CP55940 (10 μM) failed to show any further increase in GTPγS binding 
(data not shown), suggesting that reduced affinity of the agonist for those receptors is not the 
underlying cause of the partial increase of CP55940-induced GTPγS binding observed. In 
contrast, all other constitutively active receptors (L3.43A/T3.46I, T3.46I, L3.43A, L3.43A/
T3.46A, wild-type, R2.37Q/T3.46A, and R2.37A/T3.46A) exhibited a similar level of 
maximum GTPγS binding with 1 μM CP55940 treatment. This data suggest that CP55940 
induces a comparable conformation in the highly active mutant receptors (T3.46I and 
L3.43A). It would be interesting to further investigate how CP55940 docking alters the key 
salt-bridge pattern using the mutant receptors possessing different levels of constitutive 
activity.
In addition to experimentally testing structural predictions, this study permitted experimental 
testing of the extended ternary complex and related models with respect to agonist and 
inverse agonist affinity shifts.2,92,93 Using the wide activity range of CB1 receptors 
evaluated here, we have for the first time demonstrated that the activity hierarchy of these 
receptors is consistent with their ligand binding profile: the highly constitutive active 
receptor exhibits an increased affinity for agonist but decreased affinity for inverse agonist; 
the fully inactive receptor exhibits the reverse; and the partially active receptors display 
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intermediate profiles. These CB1 receptors provide a powerful framework for understanding 
the molecular basis for the multiple stages of receptor activation. These receptors also 
provide a good tool to screen for novel inverse agonists or partial agonists, which can 
selectively target receptors at different levels of activation.
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Abbreviations
BSA bovine serum albumin
CAM constitutively active mutant
CB1 cannabinoid 1 receptor
CP55940 (1R,3R,4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)-phenyl]-4-(3-
hydroxypropyl)cyclohexan-1-ol
GEnSeMBLE MC GPCR Ensemble of Structures in Membrane Bilayer Environment 
Monte Carlo
GPCR G-protein coupled receptor
GTPγS guanosine 5′-O-(3-thiotriphosophate)
HEK human embryonic kidney cell
PBS phosphate-buffered saline
SR141716A N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-
methyl-1H-pyrazole-3-carboxamide
Tm temperature midpoint of denaturation curve
TM transmembrane
TME Tris/Mg2+EDTA
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Figure 1. 
Predicted structures of the L3.43A, T3.46I, wild-type, and T3.46A receptors and their salt-
bridge patterns. The consensus structure for the T3.46A (a), wild-type (b), T3.46I (c), and 
L3.43A (d) receptors are illustrated based on the low energy conformations from 
GEnSeMBLE MC computational predictions. Key salt bridge (R2.37 + D6.30, R3.50 + 
D6.30, D3.49 + K4.41, R5.71 + D6.30 and D2.63 + K3.28) and hydrogen bond (S2.45-
T3.46) interactions in the consensus pattern are indicated by black dotted lines with red 
heteroatom distances. Note that the T3.46A receptor has a broken salt-bridge between D2.63 
and K3.28 since the inter-residue distance is 6.8 Å. (B) Comparison of the key non-covalent 
interaction patterns for each receptor. Shaded cells indicate that this salt bridge interaction is 
also observed in the wild-type receptor.
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Figure 2. 
Amino acids in TM2 and TM3 that are substituted to produce the single and double mutant 
receptors used in this study and comparison of the salt-bridge patterns of key CB1 receptors. 
(A) GEnSeMBLE MC predicted structures of TM2 and TM3 of the wild-type receptor are 
shown. The residues mutated in this study are labeled with the amino acid numbers denoting 
the Ballesteros-Weinstein nomenclature of the human CB1 receptor. (B) Comparisons of the 
key salt-bridges patterns of CB1 wild-type and mutant receptors. Blue lines connecting the 
TM helices indicate the pattern of intracellular salt-bridges identified by computational 
analysis (R2.37 + D6.30, R3.50 + D6.30, D3.49 + K4.41, and R5.71 + D6.30) as critical for 
various steps of receptor activation. The red line indicates a more extracellular salt-bridge 
(D2.63 + K3.28) critical for activation. Numbers in circles indicate the TM numbers for each 
receptor. The wild-type and mutant receptors are grouped by their predicted levels of 
constitutive activity; the highly active L3.43A and T3.46I receptors (top row); the partially 
active R2.37A/T3.46A, R2.37Q/T3.46A, and wild-type receptors (middle row); the inactive 
Ahn et al. Page 22
Proteins. Author manuscript; available in PMC 2016 May 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
T3.46A and D2.63A/L3.43A receptors (bottom row). (C) The single, double, and triple point 
mutant receptors proposed based on GEnSeMBLE MC computational predictions and 
evaluated for their biochemical properties are listed with a predicted rank order in terms of 
constitutive activity relative to the wild-type receptor.
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Figure 3. 
Comparison of basal and agonist-induced GTPgS binding to HEK293 cell membranes 
expressing the CB1 wild-type and mutant receptors. (A) The level of [35S]GTPgS binding 
was measured in the absence of ligand for the CB1 receptors to determine the level of basal 
activity. Data are presented as specific binding of GTPgS to the membrane. Nonspecific 
binding was determined in the presence of 10 mM unlabeled GTPgS. Each data point 
represents the mean ± S.E. (error bars) of at least three independent experiments performed 
in duplicate. (B) Comparison of agonist-induced GTPgS binding to HEK293 cell 
membranes expressing the CB1 wild-type and mutant receptors. The level of [35S]GTPgS 
binding was measured in the presence (black bars) of 1 μM CP55940 for the CB1 wild-type 
and mutant receptors. Nonspecific binding was determined in the presence of 10 mM 
unlabeled GTPgS. Each data point represents the mean ± SE (error bars) of at least three 
independent experiments performed in duplicate. The dashed line indicates the level of non 
CB1-mediated GTPgS binding obtained from [35S]GTPgS binding to the mock-transfected 
membrane sample. The values for GTPγS binding from the mutant receptors are compared 
to the wild-type values using analysis of variance (ANOVA) followed by Bonferroni's post 
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hoc test for significance. P values of <0.05 were considered to be statistically significant and 
indicated by the asterisk (*).
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Figure 4. 
Thermal stability of the CB1 wild-type and mutant receptors. The membrane prepared from 
HEK293 cells expressing the wild-type or mutant receptors was incubated at the indicated 
temperature for 30 minutes followed by cooling on ice as described in Materials and 
Methods. The residual binding capacity after heating the receptor relative to control was 
measured using [3H]CP55940. The data are presented as the loss of [3H]CP55940 binding 
relative to the control sample for each receptor (as described in Materials and Methods). (A) 
Receptors displaying lower apparent Tms relative to the wild-type are shown. These include 
the L3.43A/T3.46I, T3.46I, L3.43A, and L3.43A/T3.46A receptors. (B) Receptors 
displaying higher apparent Tms relative to the wild-type are shown with that of the wild-type 
receptor. These include D2.63A/L3.43A, T3.46A, R2.37A/D2.63A/L3.43A, R2.37A/
T3.46A, and R2.37Q/T3.46A. Each data point in (A) and (B) represents the mean SE (error 
bars) of three independent experiments performed in duplicate. (C) Relation of Tm and the 
basal level of [35S]GTPgS binding for all characterized receptors is shown. The line 
describes the trend. An R2 value of 0.9722 indicates a good correlation between the thermal 
stability and G protein activation ability.
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Table I
Apparent Tms of the CB1 Wild-Type and Mutant Receptors
Receptor Apparent Tm (°C)
L3.43A/T3.46I 55.8 ± 1.2
T3.46I 58.1 ± 0.7
L3.43A 57.2 ± 1.6
L3.43A/T3.46A 60.7 ± 1.1
Wild-type 64.3 ± 0.8
R2.37Q/T3.46A 67.2 ± 0.9
R2.37A/T3.46A 68.1 ± 0.9
R2.37A/D2.63A/L3.43A 69.8 ± 1.2
T3.46A 71.7 ± 1.5
D2.63A/L3.43A 72.1 ± 2.1
The apparent Tm (mean ± SE) from thermal denaturation curves for each receptor was obtained from three individual experiments done in 
duplicate.
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Table II
Ligand Binding Properties of the CB1 Wild-Type and Mutant Receptors
[3H]CP55940 [3H]SR141716A
Kd (nM) Kd ratio (receptor: 
wild-type)
Bmax (fmol/mg) Kd (nM) Kd ratio (receptor: 
wild-type)
Bmax (fmol/mg)
L3.43A/T3.46I 0.28 ± 0.02a 1:6 2603 ± 186 13.17 ± 1.72a 6:1 3637 ± 229
T3.46I 0.31 ± 0.04a 1:6 3933 ± 291 14.72 ± 2.10a 7:1 3621 ± 690
L3.43A 0.32 ± 0.13a 1:6 2974 ± 341 14.20 ± 1.87a 7:1 3859 ± 161
L3.43A/T3.46A 1.10 ± 0.23 1:1 2890 ± 108 7.50 ± 0.46a 4:1 3595 ± 205
Wild-type 1.78 ± 0.32 3724 ± 152 2.11 ± 0.42 4221 ± 284
R2.37A/T3.46A 5.58 ± 0.32a 3:1 3113 ± 263 1.67 ± 0.26 1:1 4310 ± 298
R2.37Q/T3.46A 6.21 ± 1.11a 3:1 3858 ± 444 1.59 ± 0.22 1:1 4627 ± 241
R2.37A/D2.63A/L3.43A 7.63 ± 0.89a 4:1 3201 ± 329 1.48 ± 0.20 1:1 4408 ± 303
T3.46A 9.83 ± 1.12a 6:1 3103 ± 280 0.61 ± 0.09a 1:3 4887 ± 210
D2.63A/L3.43A 12.74 ± 2.13a 7:1 3083 ± 405 0.64 ± 0.07a 1:3 3922 ± 159
Data are the mean ± SEM of three independent experiments performed in duplicate (n = 3 determinations).
aStatistically significant Kd differences from wild-type (P < 0.05) using analysis of variance (ANOVA) followed by Bonferroni's post hoc test.
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